<DOC>
	<DOCNO>NCT02431585</DOCNO>
	<brief_summary>Recently new clinical entity , gluten sensitivity ( GS ) , form gluten intolerance neither allergic autoimmune mechanism identify , add spectrum gluten-related disorder . This condition characterize gastrointestinal extra-intestinal symptom include abdominal pain ( 68 % ) ; eczema rash ( 40 % ) ; headache ( 35 % ) ; diarrhoea ( 33 % ) fatigue ( 33 % ) . The small intestine GS patient usually normal . The prevalence GS yet establish although estimate 6 % general population might affect . GS describe adult data available paediatric population.The main problem new condition , present , speciﬁc biomarkers conﬁrm GS diagnosis . In absence serological histological marker , diagnosis remain clinical . In order avoid placebo effect dietary treatment , presently GS diagnosis need perform double-blind randomized placebo-controlled challenge provide wheat allergy CD previously exclude . The primary aim study evaluate prevalence GS IBS paediatric patient . The secondary aim : 1 ) describe clinical , serologic , genetic histological profile GS patient 2 ) study role gluten possible wheat component onset GS . Study design Randomized double blind placebo control cross re-challenge trial . Patient consecutively diagnose IBS ( Rome III criterion ) diagnosis coeliac disease wheat allergy exclude , consider eligible study . Diagnosis coeliac disease wheat allergy exclude negativity TTG-IgA and/or EMA Skin Prick Test , RAST immuno-CAP Atopy patch test respectively . Patients enter three-phase study run phase ( phase I : week 1-2 ) , diagnostic elimination diet phase ( phase II : week 3-4 ) re-challenge phase ( phase III : week 5-12 )</brief_summary>
	<brief_title>Prevalence Gluten Sensitivity Irritable Bowel Syndrome : The First Study Paediatrics .</brief_title>
	<detailed_description>Randomized double blind placebo control cross re-challenge trial . Patient consecutively diagnose IBS ( Rome III criterion ) diagnosis coeliac disease wheat allergy exclude , consider eligible study . Diagnosis coeliac disease wheat allergy exclude negativity TTG-IgA and/or EMA Skin Prick Test , RAST immuno-CAP Atopy patch test respectively . Patients enter three-phase study run phase ( phase I : week 1-2 ) , diagnostic elimination diet phase ( phase II : week 3-4 ) re-challenge phase ( phase III : week 5-12 ) . The following procedure perform different time ( Table 1 ) : 1 . Entry ( Time 0 ) : Blood test , HLA blood spot , collection urine stool ; 2 . Running-in ( phase I : week 1-2 ) : Visual Analogue Scale ( VAS ) ( IBS-SS ) ; STAIC test ; Bristol stool chart ( mBSFC ) , extra-intestinal symptom questionnaire . At end week 2 patient still complain IBS symptom ( IBS-SS &gt; 75 ) proceed trial undergo endoscopy plus biopsy voluntary basis . 3 . Diagnostic gluten elimination diet phase ( phase II : week 3-4 ) : Visual Analogue Scale ( VAS ) ( IBS-SS ) ; STAIC test ; Bristol stool chart ( mBSF-C ) , extra-intestinal symptom questionnaire . Collection urine stool ( end week 4 ) . At end week 4 patient significant reduction IBS symptom VAS ( great 30 % ) proceed re-challenge phase . The challenge phase subdivide Two phase : one double blind phase ( product A B ) plus single blind phase ( product C ) . 4 . Product A ( week 5-6 ) : Visual Analogue Scale ( VAS ) ( IBS-SS ) , STAIC test ; Bristol stool chart ( mBSF-C ) , extra-intestinal symptom questionnaire , collection urine stool ( end week 6 ) ; 5 . Product B ( week 8-9 ) : Visual Analogue Scale ( VAS ) ( IBS-SS ) , STAIC test ; Bristol stool chart ( mBSF-C ) , extra-intestinal symptom questionnaire , collection urine stool ( end week 9 ) 6 . Product C ( week 11-12 ) : Visual Analogue Scale ( VAS ) ( IBS-SS ) , STAIC test ; Bristol stool chart ( mBSF-C ) , extra-intestinal symptom questionnaire , collection urine stool ( end week 12 ) Challenge procedure Double Blind phase ( Product A B ) : Children ask keep follow strict gluten free diet take sachet daily period two week intersperse washout phase one week . Sachet contain either pure gluten ( 10 gram daily ) gluten free flour ( 10 gram daily - SHAR ) . Sachets contain placebo shape , dimension , indication appearance contain gluten provide bag factory , ensure study blind investigator patient . Sachets name A B . Single Blind Challenge ( Product C ) : To assess whether component wheat gluten involve onset GS , child ask take period two week , gluten free diet , muffin make wheat flour single blind fashion .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Age 418 year ; IBS diagnosis accord Roma III criterion ; Written inform consent . Coeliac disease ; Wheat allergy ; Others food allergy ; Type 1 Diabetes ; Others Chronic Malignant diseases ; H. Pylori infection .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>abdominal pain</keyword>
	<keyword>gluten free diet</keyword>
	<keyword>functional gastrointestinal disorder</keyword>
</DOC>